申请人:Eli Lilly and Company
公开号:US06177426B1
公开(公告)日:2001-01-23
The compound, ((3(2-amino-1,2-dioxoethyl)-1-((1,1′-biphenyl)-3-ylmethyl)-2-methyl-1H-indol-4-yl)oxy)acetic acid morpholino-ethyl ester, is disclosed together with its use as a highly bioavailable indole compound for inhibiting sPLA2 mediated release of fatty acids for treatment of conditions such as septic shock.
这种化合物,((3(2-氨基-1,2-二氧乙基)-1-((1,1′-联苯)-3-基甲基)-2-甲基-1H-吲哚-4-基氧基)乙酸吗啡啶乙酯),以及其作为一种高生物利用度的吲哚化合物用于抑制sPLA2介导的脂肪酸释放,用于治疗诸如感染性休克等疾病的用途被披露。